ATE366812T1 - Neue methode zur erkennung eines stoffes, der die interaktion zwischen einem tnf-liganden und seinem rezeptor auf b-zellen moduliert - Google Patents

Neue methode zur erkennung eines stoffes, der die interaktion zwischen einem tnf-liganden und seinem rezeptor auf b-zellen moduliert

Info

Publication number
ATE366812T1
ATE366812T1 AT99950598T AT99950598T ATE366812T1 AT E366812 T1 ATE366812 T1 AT E366812T1 AT 99950598 T AT99950598 T AT 99950598T AT 99950598 T AT99950598 T AT 99950598T AT E366812 T1 ATE366812 T1 AT E366812T1
Authority
AT
Austria
Prior art keywords
modulates
receptor
interaction
substance
cells
Prior art date
Application number
AT99950598T
Other languages
English (en)
Inventor
Stuart Neville Farrow
Allard Kaptein
Jeremy David Alisdair Kitson
Alison Janet Winder
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10845021&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366812(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE366812T1 publication Critical patent/ATE366812T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99950598T 1998-12-23 1999-10-05 Neue methode zur erkennung eines stoffes, der die interaktion zwischen einem tnf-liganden und seinem rezeptor auf b-zellen moduliert ATE366812T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828628.9A GB9828628D0 (en) 1998-12-23 1998-12-23 Novel ligand

Publications (1)

Publication Number Publication Date
ATE366812T1 true ATE366812T1 (de) 2007-08-15

Family

ID=10845021

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99950598T ATE366812T1 (de) 1998-12-23 1999-10-05 Neue methode zur erkennung eines stoffes, der die interaktion zwischen einem tnf-liganden und seinem rezeptor auf b-zellen moduliert

Country Status (8)

Country Link
US (4) US7399593B1 (de)
EP (2) EP1141283B1 (de)
AT (1) ATE366812T1 (de)
AU (1) AU6332399A (de)
DE (1) DE69936538T2 (de)
ES (2) ES2289825T3 (de)
GB (1) GB9828628D0 (de)
WO (1) WO2000039295A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
IL144202A0 (en) 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
CN100447244C (zh) 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
US20070249530A1 (en) 2004-01-29 2007-10-25 Genentech, Inc. Bcma Polypeptides and Uses Thereof
EP2332563A3 (de) 2004-10-13 2013-03-13 The Washington University Verwendung von BAFF zur Behandlung von Sepsis
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EP1922080A2 (de) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Verfahren zur behandlung von b-zell-malignomen mittels taci-ig-fusionsmolekül
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007142667A2 (en) * 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
BRPI0711823A2 (pt) 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
WO2010093993A2 (en) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
GB201510758D0 (en) * 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) * 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
PT939804E (pt) * 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
AU7608898A (en) * 1997-06-06 1998-12-21 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
JP2002504818A (ja) * 1997-06-06 2002-02-12 リジェネロン ファーマシューティカルズ，インコーポレイテッド リガンドファミリーのｎｔｎ−２メンバー
EP1012270A2 (de) 1997-09-12 2000-06-28 Apotech R&D S.A. Kay: ein neues immunsystem-protein
US6157933A (en) 1997-11-26 2000-12-05 International Business Machines Corporation Method and apparatus for loading multiple animated images on a web-page with limited network throughput
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
IL144202A0 (en) 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
CN100447244C (zh) 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci

Also Published As

Publication number Publication date
WO2000039295A1 (en) 2000-07-06
US8784814B2 (en) 2014-07-22
DE69936538T2 (de) 2008-03-13
AU6332399A (en) 2000-07-31
ES2621858T3 (es) 2017-07-05
EP1847608A1 (de) 2007-10-24
EP1847608B1 (de) 2017-01-25
GB9828628D0 (en) 1999-02-17
EP1141283B1 (de) 2007-07-11
ES2289825T3 (es) 2008-02-01
US7399593B1 (en) 2008-07-15
US20150197565A1 (en) 2015-07-16
US8216576B2 (en) 2012-07-10
US20090098129A1 (en) 2009-04-16
EP1141283A1 (de) 2001-10-10
DE69936538D1 (de) 2007-08-23
US20140056900A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
ATE366812T1 (de) Neue methode zur erkennung eines stoffes, der die interaktion zwischen einem tnf-liganden und seinem rezeptor auf b-zellen moduliert
IL124728A0 (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
DE60035163D1 (de) Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
NZ527053A (en) Modified amyloid precursor protein polynucleotides and polypeptides
BR9912545A (pt) ácidos nucleicos codificando um receptorcopulado a proteìna g envolvido em transduçãosensorial
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
DE3765138D1 (de) Mehrschichtiges element zur quantitativen analyse von immunoreagenzien.
EP0299741A3 (de) Verfahren und Vorrichtung zur Sequenzierung von Proteinen oder Peptiden
DE69432449D1 (de) Verfahren zur Herstellung von hydrophoben Polypeptiden, Proteinen und Peptiden
ATE152481T1 (de) Neue polypeptide, dna-sequenzen, die deren expression erlauben, verfahren zur vorbereitung und verwendung
AP9901607A0 (en) Method and apparatus for continuous flow isoelectric focusing for
DE60014575D1 (de) Stabilisierende Peptide, und Polypeptide und Antikörper die diese beinhalten
ATE165363T1 (de) Verfahren und mittel zur sortierung und bestimmung biologischer informationen
EP1609864A3 (de) Verwendung von dem neuronalen Apoptosehemstoff Protein (NAIP)
EP1203775A3 (de) Chemoattraktion-auslösender Faktor aus Lymphozyten und dessen Verwendung
FI863626A7 (fi) DNA-sekvenssejä, yhdistelmä-DNA -molekyylejä ja menetelmiä ihmisen lip okortiinin kaltaisia polypeptidejä.
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
DE69626522D1 (de) Peptide mit pronociceptiveigenschaften
ATE301712T1 (de) Z2-19a, ein menschliches homolog von dem protein 2-19
DE69635739D1 (de) Verwendung eines sec-abhängigen sekretionssystems zur sekretion von proteinen, welche gewöhnlich durch ein sec-unabhängiges sekretionssystem sekretiert werden
DK1342729T3 (da) Antistoffer og antisense-molekyler for G-koblet receptor der udviser selektiv affinitet for ATP
ATE223056T1 (de) Diagnose von neuro-degenerativen erkrankungen
DE69327167D1 (de) Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties